Vericel Corporation (VCEL)
NASDAQ: VCEL · Real-Time Price · USD
42.65
+0.92 (2.20%)
At close: May 12, 2025, 4:00 PM
42.65
0.00 (0.00%)
After-hours: May 12, 2025, 4:39 PM EDT
Vericel Market Cap
Vericel has a market cap or net worth of $2.15 billion as of May 12, 2025. Its market cap has decreased by -3.57% in one year.
Market Cap
2.15B
Enterprise Value
2.12B
1-Year Change
-3.57%
Ranking
Category
Stock Price
$42.65
Market Cap Chart
Since December 1, 1998, Vericel's market cap has increased from $31.90M to $2.15B, an increase of 6,630.81%. That is a compound annual growth rate of 17.25%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
May 9, 2025 | 2.10B | -22.49% |
Dec 31, 2024 | 2.71B | 59.48% |
Dec 29, 2023 | 1.70B | 36.63% |
Dec 30, 2022 | 1.24B | -32.39% |
Dec 31, 2021 | 1.84B | 31.15% |
Dec 31, 2020 | 1.40B | 80.38% |
Dec 31, 2019 | 777.70M | 3.12% |
Dec 31, 2018 | 754.20M | 296.53% |
Dec 29, 2017 | 190.20M | 163.07% |
Dec 30, 2016 | 72.30M | 17.75% |
Dec 31, 2015 | 61.40M | -15.08% |
Dec 31, 2014 | 72.30M | 412.77% |
Dec 31, 2013 | 14.10M | -74.46% |
Dec 31, 2012 | 55.20M | -21.48% |
Dec 30, 2011 | 70.30M | -2.77% |
Dec 31, 2010 | 72.30M | 35.14% |
Dec 31, 2009 | 53.50M | -20.74% |
Dec 31, 2008 | 67.50M | -2.17% |
Dec 31, 2007 | 69.00M | -53.19% |
Dec 29, 2006 | 147.40M | -32.17% |
Dec 30, 2005 | 217.30M | 65.88% |
Dec 31, 2004 | 131.00M | 38.19% |
Dec 31, 2003 | 94.80M | 321.33% |
Dec 31, 2002 | 22.50M | -45.78% |
Dec 31, 2001 | 41.50M | 40.20% |
View and export this data all the way back to 1998.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
Eli Lilly and Company | 659.45B |
Johnson & Johnson | 371.06B |
UnitedHealth Group | 345.29B |
AbbVie | 326.08B |
Novo Nordisk | 297.79B |
Abbott Laboratories | 231.82B |
Novartis AG | 214.71B |
AstraZeneca | 211.14B |